Welcome to our dedicated page for Mesoblast SEC filings (Ticker: MESO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mesoblast Limited (MESO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. Mesoblast files annual reports on Form 20-F and frequent Form 6-K reports that incorporate announcements made to the Australian Securities Exchange. These filings cover topics such as quarterly cash flow reports (Appendix 4C), new issue announcements (Appendix 3G), changes in directors’ interests (Appendix 3Y), and investor presentations.
For investors analyzing Mesoblast’s biotechnology business, the filings are a primary source of information on its allogeneic mesenchymal stromal cell platform, the commercial performance of Ryoncil for pediatric steroid-refractory acute graft versus host disease, and the development of product candidates like rexlemestrocel-L for chronic low back pain and heart failure. The company’s disclosures also describe its extensive intellectual property portfolio, proprietary manufacturing processes for cryopreserved off-the-shelf cellular medicines, and financing arrangements such as credit facilities and convertible notes.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from long filings, helping readers quickly understand material changes, risk factor updates, and financing terms. Users can review real-time 6-K updates pulled from EDGAR, as well as annual 20-F reports that provide detailed discussion of Mesoblast’s operations, cell therapy pipeline, and risk profile.
In addition, this page offers convenient access to information related to equity issuance, corporate governance, and director transactions referenced in Mesoblast’s cross-filed ASX appendices. By combining original SEC documents with AI-generated overviews, the filings section helps investors, analysts, and researchers interpret Mesoblast’s regulatory reporting without reading every page line by line.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer, primarily to furnish investors with copies of two equity-related announcements it filed with the Australian Securities Exchange on January 15, 2026. One attached exhibit is an Appendix 3H covering a cessation of securities, and the other is an Appendix 3G relating to the issue, conversion or payment up of unquoted equity securities. These ASX appendices are included as Exhibits 99.1 and 99.2 so U.S. investors can access the same equity capital changes information filed in Australia.
Mesoblast Limited submitted a foreign issuer report describing an action first disclosed on the Australian Securities Exchange. On December 17, 2025, the company lodged an Appendix 3G with the ASX, which relates to a new issue announcement and the issue, conversion or payment up of unquoted equity securities. This Appendix 3G document is attached to the report as an exhibit and is incorporated by reference for further details.
Mesoblast Limited furnished a Form 6-K to provide investors with Australian Securities Exchange materials. The filing attaches two ASX documents dated October 28, 2025: an Appendix 3Y change of director’s interest notice and an Appendix 3G notification of issue, conversion or payment up of unquoted equity securities, incorporated by reference as Exhibits 99.1 and 99.2.
This update is administrative, making the ASX disclosures available to U.S. investors under the Exchange Act.
Mesoblast Limited furnished a Form 6-K to provide investors with its Australian Securities Exchange Appendix 4C quarterly report for the quarter ended September 30, 2025. The Appendix 4C is attached as Exhibit 99.1 and incorporated by reference. The filing is an administrative submission linking U.S. investors to the company’s ASX quarterly cash flow and activities report.
Mesoblast Limited Schedule 13G/A filed for ordinary shares/ADRs reports that Gregory George, his sons James and Grant George, and G to the Fourth Investments, LLC collectively hold substantial positions as of September 11, 2025. Gregory George is reported as beneficial owner of 275,851,734 shares in the aggregate (21.59% of the 1,277,782,187 outstanding shares), including 137,123,887 shares he solely owns and discretionary voting or dispositive authority over additional shares held by G to the Fourth Investments and by his sons. G to the Fourth Investments, LLC holds 126,727,847 shares (9.92%). James George and Grant George each report 6,000,000 shares (0.47% each). The filing states the holdings were not acquired to change or influence control.
Mesoblast is a commercial-stage biotech focused on allogeneic mesenchymal lineage cell therapies. The company received FDA approval in December 2024 for remestemcel-L (Ryoncil®) to treat steroid-refractory acute graft-versus-host disease in pediatric patients and launched the product in March 2025. Since launch through June 30, 2025, Mesoblast reported net product sales of $11.3 million.
The company reported a net loss of $102.1 million for the year ended June 30, 2025 and cumulative losses of $1,010.9 million since inception. At June 30, 2025 Mesoblast held $161.6 million in cash and reported net cash usage from operations of $50.0 million for the year. Management states current cash plus forecasted Ryoncil® revenue are sufficient to meet operating cash needs for the next 12 months, and they expect to refinance existing borrowings within that period. The company remains dependent on third-party manufacturers, certain single-source suppliers and successful commercialization, and highlights multiple operational, regulatory and market risks that could affect future results.
FAQ
What is the current stock price of Mesoblast (MESO)?
What is the market cap of Mesoblast (MESO)?
